

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-76. (Cancelled)

77. (Currently amended) ~~An isolated protein comprising~~ A monomeric single-chain Fv (sFv) molecule, said sFv molecule consisting essentially of :

(a) a first polypeptide domain comprising an ordered arrangement of three complementarity determining regions (CDRs) interposed between framework regions (FRs), said FRs derived from a human immunoglobulin, wherein the first polypeptide domain comprises an amino acid sequence of the general formula FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and;

(b) a second polypeptide domain comprising an ordered arrangement of three CDRs interposed between FRs, said FRs derived from a human immunoglobulin, wherein the second polypeptide domain comprises an amino acid sequence of the general formula FR1'-CDR1'-FR2'-CDR2'-FR3'-CDR3'-FR4', wherein each of CDR1, CDR2, CDR3, CDR1', CDR2' and CDR3' is the sequence of amino acids found at amino acid positions 31-35 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 50-66 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 99-104 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 157-167 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 183-189 of SEQ ID NO:6 and the sequence of amino acids found at amino acid positions 222-230 of SEQ ID NO:6, respectively, and further wherein said first and second polypeptide domains together are capable of forming a binding site for c-erbB-2.

78. (Currently amended) ~~The protein~~ sFv molecule of claim 77, wherein said first and second polypeptides together are capable of forming a humanized antibody.

79. (Currently amended) The ~~protein~~ sFv molecule of claim 78, wherein said FR sequences are human immunoglobulin framework region sequences of a human myeloma antibody.

80. (Currently amended) The ~~protein~~ sFv molecule of claim 77, wherein the first and second polypeptide domains are linked by a polypeptide linker.

81. (Currently amended) The ~~protein~~ sFv molecule of claim 80, wherein the polypeptide linker comprises at least 10 amino acids.

82. (Currently amended) The ~~protein~~ sFv molecule of claim 81, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

83. (Currently amended) The ~~protein~~ sFv molecule of claim ~~77~~ 78, wherein the first and second polypeptide domains are linked by a polypeptide linker.

84. (Currently amended) The ~~protein~~ sFv molecule of claim 83, wherein the polypeptide linker comprises at least 10 amino acids.

85. (Currently amended) The ~~protein~~ sFv molecule of claim 84, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

86. (Currently amended) The ~~protein~~ sFv molecule of claim 84, comprising the sequence of amino acids of SEQ ID NO:6.